Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis
Anna Skakodub, Henry Walch, Kathryn R. Tringale, Jordan Eichholz, Brandon S. Imber, Harish N. Vasudevan, Bob T. Li, Nelson S. Moss, Kenny Yu, Boris Mueller, Simon N. Powell, Pedram Razavi, Helena A. Yu, Jorge S. Reis‐Filho, Daniel R. Gomez, Nikolaus Schultz, Luke Pike
Abstract
Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical data, and a lack of comparison with paired extracranial specimens. Here we report a cohort of 233 patients with resected and sequenced (MSK-IMPACT) NSCLC BM and comprehensive clinical data. With matched samples (47 primary tumor, 42 extracranial metastatic), we show CDKN2A/B deletions and cell cycle pathway alterations to be enriched in the BM samples. Meaningful clinico-genomic correlations are noted, namely EGFR alterations in leptomeningeal disease (LMD) and MYC amplifications in multifocal regional brain progression. Patients who developed early LMD frequently have had uncommon, multiple, and persistently detectable EGFR driver mutations. The distinct mutational patterns identified in BM specimens compared to other tissue sites suggest specific biologic underpinnings of intracranial progression.